Circulation：双联抗血小板治疗降低缺血性脑卒中复发风险述评.pdf

Editorial A Little Good… Steven K. Feske, MD My grandmother used to say, “If a little’ll do a little good, of the accumulated strokes of the two groups remained equal. a lot’ll do a lotta good.” Unfortunately, it is not that Therefore, with only 21 days of dual therapy, the dual-agent simple with antiplatelet agents. group retained its advantage at 3 months. The CHANCE trial was well designed and well executed. The main questions Article see p 1656 that remain concern the reproducibility and generalizability Many relevant facts are well established. In identifiable of this result. subgroups of patients who present with transient ischemic The question of generalizability primarily concerns the attacks (TIAs) or minor strokes, the risk of a subsequent population studied in the CHANCE trial. The CHANCE stroke is high.1–3 Most of this risk is incurred during the first patients were enrolled in China where the rate of intracranial few days after a warning event.2 Aspirin and other antiplatelet atherosclerosis is higher than in western populations. They 4,5 agents can lower the risk of secondary stroke by ≈12–22%. were all enrolled within 24 hours of the event. The event was In patients with acute corona